Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 5/20 | 0.37 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.37 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.34 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ATM | Q13315 | 1/20 | 0.33 |
| ▸ | NAAA | Q02083 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | CA2 | P00918 | 1/20 | 0.31 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.31 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.31 |
| ▸ | PPARG | P37231 | 2/20 | 0.31 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.31 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14815508 | 0.81 | ESR1 (0.39) | ESR1ESR2KCNH2ATM | |
| SCHEMBL14815649 | 0.79 | PTGS2 (0.30) | — | |
| SCHEMBL14829473 | 0.78 | PPARG (0.36) | CA1CA2PPARG | |
| SCHEMBL14815087 | 0.77 | CYP17A1 (0.50) | — | |
| SCHEMBL19292671 | 0.74 | — | — | |
| SCHEMBL14815373 | 0.72 | ERN1 (0.36) | NAAA | |
| SCHEMBL14829629 | 0.72 | MCHR1 (0.38) | NAAA | |
| SCHEMBL14814851 | 0.70 | HSD11B1 (0.50) | GRIN2BGRIN1 | |
| SCHEMBL14815002 | 0.69 | MKNK1 (0.55) | — | |
| SCHEMBL14815530 | 0.69 | PDGFRB (0.51) | ESR1ESR2KCNH2CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2760854-B1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| EP-2760854-B1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ASANA BIOSCIENCES LLC (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9199975-B2 | Biaryl imidazole derivatives for regulating CYP17 | ASANA BIOSCIENCES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199975-B2 | Biaryl imidazole derivatives for regulating CYP17 | ASANA BIOSCIENCES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-9199975-B2 | Biaryl imidazole derivatives for regulating CYP17 | ASANA BIOSCIENCES, LLC (US) | 2015-12-01 | — | — | US | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| US-20130085164-A1 | Imidazole Derivatives | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | US | disclosed |
| WO-2013049565-A1 | IMIDAZOLE DERIVATIVES AS CYP17 INHIBITORS FOR THE TREATMENT OF CANCER | ENDO PHARMACEUTICALS INC. (US) | 2013-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130085164-A1 | Imidazole Derivatives | CYP17A1, CYP2A7, CYP11B1 | ESR1 624/4885ESR2 2127/4885PDE10A 766/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.